NEW YORK – ProciseDx and Lumiphore today announced that they have inked an agreement to incorporate Lumiphore's metal luminescent reporter technology into ProciseDx's rapid, quantitative point-of-care diagnostic tests.
Under the agreement, San Diego-based ProciseDx has the exclusive worldwide rights to use Lumiphore's reporter technology in its diagnostic tests.
Financial and other terms of the agreement were not disclosed.
ProciseDx said it expects to launch the first products to use the technology in 2020 for inflammatory and autoimmune diseases, such as celiac and metabolic syndromes.
Steve Blose, chief business officer of Berkeley, California-based Lumiphore, said in a statement that his firm offers "the benefits of lanthanide-based homogenous mix-and-read assays, known as time-resolved fluorescence resonance energy transfer assays," to diagnostic applications in central labs and at the point of care.
He added that "detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore's new reporter technology."